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Abstract
The SINERGIE (South Italian Network for Rational Guidelines and International Epidemiology) project is intended to
set up a collaborative network comprising virologists, clinicians and public health officials dealing with patients
affected by HCV disease in the Calabria Region. A prospective observational data-base of HCV infection will be
developed and used for studies on HCV natural history, response to treatment, pharmaco-economics, disease
complications, and HCV epidemiology (including phylogenetic analysis). With this approach, we aim at improving
the identification and care of patients, focusing on upcoming research questions. The final objective is to assist in
improving care delivery and inform Public Health Authorities on how to optimize resource allocation in this area.
Mission, general objectives, and framework
The mission of the SINERGIE Study Group is to imple-
ment evidence-based research on Hepatitis C virus (HCV)
into practice. We recognize that evidence from rando-
mized clinical trials (RCT) is not fully informative in the
clinical practice because patients are selected for inclusion
into RCT based on strict criteria and study design is often
not transferable to the diverse circumstances encountered
in clinical practice. In fact, patients treated in clinical prac-
tice may be affected by bio-psycho-social co-morbidities
that can affect treatment acceptability, retention into care,
and outcome. Therefore, there is a need to ascertain treat-
ment effectiveness in clinical practice, improve treatment
algorithms based on clinical needs, and study their cost-
effectiveness through pharmaco-economical analyses.
Also, we will try to understand the transferability and the
clinical outcomes of existing guidelines for treatment of
HCV to guide future policy. In conclusion, we wish to
improve the identification and care of patients infected
with HCV in the Calabria Region (South Italy), focusing
on upcoming research questions that will most advance
knowledge in this area and assist in improving care deliv-
ery and optimizing resource allocation.
With this objective in mind, we have put together
experts from different fields, following a patient-centered
approach. In this framework, virologists, infectious disease
specialists, gastroenterologists, and public health officials
will be called to perform a coordinated effort to adapt the
current international guidelines to the specificities and
resources available to the Calabria Region’s Health System.
Periodical audits will also be conducted and discussed dur-
ing the annual meetings of the SINERGIE Study Group.
To support our mission, we have developed three over-
arching goals: (1) Better disease identification, (2) Better
disease management, and (3) Improved access and equity.
Goal 1 recognizes that the benefit of better disease
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management depends first and foremost on identifying
infected individuals and linking them to care. Through
an improvement in the screening policy of the general
population, we will obtain more reliable estimates of the
HCV epidemics in order to provide public health officials
with relevant information on the status and evolution of
the epidemics as a basis for a targeted prevention policy.
Phylogenetic analysis will help to understand HCV trans-
mission routes within our population. Goal 2 acknowl-
edges the need for patient-centered, comprehensive,
coordinated care and treatment that not only addresses
the viral infection but also the social environment, men-
tal and physical complications that affect patients’ out-
come. This will take advantage from involvement of
specialist clinicians with complementary knowledge,
skills and abilities. Goal 3 reaches out to infected patients
at highest risk for impaired access, including migrants,
the homeless, rural residents, and those with mental
health and substance use disorders.
In achieving these goals, we hope to promote a more
general understanding of implementation science, con-
tribute to theory development, incorporating the public
health assistance philosophy guaranteed by the Italian
legislation, and diffusion of innovation frameworks. We
will propose to extend this program to other Regions
throughout Italy.
Specific research questions and methods
We will conduct a multicenter, prospective, observa-
tional study. We recognize that the ability of clinicians
to treat HCV patients appropriately will largely depend
on a better prediction of the clinical response from a
global perspective. In other terms, several variables need
to be studied further and integrated into algorithms sub-
jected to clinical validation. The integration of clinical,
virological and epidemiological data of the HCV patients
included in the SINERGIE database is expected to pro-
vide a convenient platform for investigating virus-host
interactions in the context of anti-HCV treatment. This
can result in models to be applied as a treatment deci-
sion support system. Furthermore, the data collected
will be used for the molecular monitoring of HCV epi-
demiology. The general plan of the study (including
types of variables –i.e., attributes- recorded) is illustrated
in Figure 1.
A. Clinical and metabolic attributes
Amongst the open questions on the treatment of
chronic HCV infection, the following merit to be
answered: (i) What is the actual impact of metabolic co-
morbidities and/or alcohol abuse on the efficacy of anti-
viral therapy [1]?; (ii) What is the socio-demographic
profile of the HCV population and how this impact on
Figure 1 Flow of interventions and objectives of the SINERGIE study
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access to treatment and acceptability, retention into
care, and treatment outcome [2]?
To try to answer these questions, the project aims at
establishing a database of variables that can be analyzed
for their association with or prediction of HCV treatment
outcome. In particular: age; gender (dichotomized as male,
female, and transgender); race/ehnicity (for the analysis,
race/ethnicity will be categorized into four categories:
white, black, Hispanic, and other/unknown); previous or
current substance abuse and types of substances used
(substance abuse will be coded as present if an ICD-9 code
for substance abuse/dependence is present); previous or
current alcohol abuse (the diagnosis of alcoholism will be
made based on either the DSM-IIIR or the DSM-IV cri-
teria, or the judgment of the physician for alcohol abuse,
based on the history of excessive and persistent alcohol
consumption - >20 g ethanol/day for women and >40 g
ethanol/day for men, for almost 10 years - along with com-
patible physical examination and laboratory test abnormal-
ities); HIV positivity (HIV will be coded as present for a
positive antibody test confirmed by a western blot or posi-
tive HIV RNA); HBsAg positivity; current or previous
sexually transmitted disease; stage of liver disease (in parti-
cular, end-stage of liver disease, the complications of cir-
rhosis, such as ascites, hepato-renal syndrome, variceal
bleeding, hepatic encephalopathy, spontaneous bacterial
peritonitis, will be collected); anthropometric parameters
(body weight, height, waist and hip circumferences, waist/
hip ratio and body mass index, will be evaluated and col-
lected); biochemical parameters (such as liver markers for
intracellular damage, parameters related to metabolic syn-
drome, will be collected). Ultrasonographic evaluation of
the liver parenchyma, portal hemodynamic and spleen sta-
tus, transient elastography and biochemical non invasive
measures will also be monitored and reported at least in a
sub-set of patients where these tools are available.
B. Pharmacogenomic attributes
Recently, different interleukins have been associated with
HCV natural history, responses to pegIFN/RBV, and spon-
taneous clearance of acute HCV infection. In particular,
IL28B single nucleotide polymorphisms are associated
with spontaneous and treatment-induced clearance of
HCV, so treatment guidelines recommend to perform a
pharmacogenomic screening before prescribing HCV
treatment [3]. However, since other genes may be impli-
cated [4], it is important to conduct pharmacogenomic
studies aimed at validating inclusion of interleukin genes
polymorphisms into diagnostic and therapeutic algorithms
of HCV infection.
C. Virological attributes and phylogenetic analysis
Genetic variability is a major hallmark of HCV biology.
Currently available HCV sequences can be grouped into
6 genotypes, each further sub-divided into several
subtypes [5]. The clinical impact of HCV variability has
been known since interferon (IFN) based anti-HCV
therapy has been introduced in the clinic. Indeed, nat-
ural susceptibility to IFN and hence to the standard of
care pegylated IFN plus ribavirin (pegIFN/RBV) varies
significantly with different HCV genotypes [6]. In parti-
cular, HCV genotype 1, the most prevalent in Western
countries, appears to be much less sensitive to pegIFN/
RBV compared to other genotypes. Other genetic pre-
dictors of response to pegIFN/RBV include specific ami-
noacid variants in the core protein (Arg70 and Leu91) [7]
and the composition of the short interferon sensitivity-
determining region (ISDR) and interferon and ribavirin
resistance-determining region (IRRDR) in the NS5A cod-
ing sequence [8,9]. This has established routine designa-
tion of HCV genotype through molecular assays as a
screening test whenever HCV treatment is considered.
Subsequently, the relative inability to eradicate HCV gen-
otype 1 infection by pegIFN/RBV has fuelled large invest-
ments ultimately resulting in the development and
licensing of the first directly acting antivirals (DAA).
Availability of the first two HCV NS3/4A protease inhibi-
tors (boceprevir [BVR] and telaprevir [TVR]) has signifi-
cantly expanded treatment options and increased the rate
of sustained virological response (SVR) [10]. However,
adding the current HCV NS3/4A protease inhibitors to
the standard pegIFN/RBV therapy has also increased
treatment complexity and toxicity.
Given the unprecedented number of compounds being
developed against different targets in HCV life cycle
[11], monitoring HCV variability through HCV genome
sequencing in patients candidate to or under treatment
could become an integral part of the clinical manage-
ment of HCV infection [12]. At this time, it is not possi-
ble to foresee to what extent HCV genome sequencing
will remain a research need or will be commonly used
in clinical practice. Recent trials have shown that HCV
drug resistance is frequently detected at treatment fail-
ure of NS3/4A protease inhibitors based therapy [13].
Specific drug resistance mutations have been found
which are preferentially associated with BVR or TVR
and with HCV genotype 1a or 1b. Since no trial on
DAA-pretreated subjects has been completed, it is diffi-
cult to weight the cost-benefit of drug resistance testing
after virological treatment failure. Likewise, the role of
genotypic testing beyond genotype and subtype assign-
ment before treatment with DAA is still a matter of
debate. Limited analysis of data derived from BVR and
TVR phase III trials have suggested that treatment fail-
ure due to pre-existent naturally resistant HCV strains
has been negligible or hardly detectable [14]. However,
majority drug resistance mutations for most DAAs have
been documented in a small but variable fraction of
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untreated subjects in several studies [15-18]. Although
understanding the dynamics of DAA resistance in vivo
is clearly of interest, expert HCV clinicians may well
argument that given the low prevalence and impact of
natural resistance and the future availability of many
and mostly non-cross-resistant DAA classes there is no
clinical need for genotypic resistance testing.
The SINERGIE project aims at improving care of HCV
infected patients through integration of clinical, epidemio-
logical, virological and biostatistics expertise. Data collected
from these domains into a dedicated on-line database will
be analyzed and used to derive patient tailored treatment
protocols. The individual HCV strain of each patient
included in the database will be characterized for genotype
(sequencing of the 5’UTR plus partial core region including
the aminoacid sites impacting response to pegIFN/RBV),
NS3 sequence (detection of natural polymorphisms poten-
tially affecting susceptibility to NS3/4A protease inhibitors)
and NS5A sequence (analysis of the ISDR and IRRDR
regions). Patients undergoing NS3/4A protease inhibitor
therapy will be monitored for development of NS3/4A pro-
tease inhibitor resistance according to reference guidelines
[19,20]. Along with development and licensing of novel
DAA classes, sequence analysis at baseline and at treatment
failure will be extended to other HCV genome regions, e. g.
the NS5B RNA-dependent RNA-polymerase gene. Upon
insertion into the SINERGIE database, HCV sequences will
be checked for quality assurance (e. g., detection of stop
codons, excessive degeneration, frameshift mutations,
uncommon aminoacids), assigned genotype and subtype
and processed for extraction of mutations with respect to
the reference strain. Mutations detected will be matched to
the reference DAA resistance mutation list and a report
indicating the inferred susceptibility to available DAA will
be automatically generated.
As for the epidemiological objective, storing HCV
sequences in the SINERGIE database will allow phyloge-
netic and phylogeographic studies exploring the relation-
ships among different clusters of specific HCV variants
and patient population features such as transmission
routes, origin of viral strains, time of acquisition of infec-
tion. This information can generate and periodically
refresh a dynamic picture of the circulation of the different
HCV strains in the area under analysis.
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